Regeneron Pharmaceuticals Inc

Latest Regeneron Pharmaceuticals Inc News and Updates

  • Face covering mask sign at airport after omicron announcement
    Company & Industry Overviews

    Regeneron's Stock Forecast Is in Question as Omicron Variant Spreads

    Regeneron stock could face more obstacles. Will the omicron variant of the COVID-19 virus redefine the pandemic's trajectory? What's the forecast for the stock?
    By Rachel Curry
  • COVID-19 patient in hospital being treated for virus
    Company & Industry Overviews

    Is Regeneron's COVID-19 Drug Better Than the Vaccine?

    The FDA authorized a COVID-19 drug cocktail from Regeneron, but that doesn't mean it's better than the vaccine.
    By Rachel Curry
  • Intellia scientist in lab working on CRISPR technology
    News

    CRISPR Stocks Are Soaring Amid Biotech Breakthrough

    CRISPR technology companies Intellia and Regeneron have made a major breakthrough for the industry. How will CRISPR stocks respond?
    By Rachel Curry
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Restricted Access Continues to Impact Praluent Sales in 2016

    Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

    By Margaret Patrick
  • uploads///Relative valuation
    Earnings Report

    Regeneron Continues to Trade at Premium

    Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

    By Jillian Dabney
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///Eylea sales
    Earnings Report

    Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?

    Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for United Therapeutics?

    23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

    By Margaret Patrick
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///share price
    Earnings Report

    Understanding Regeneron’s Share Price Movement after Its 4Q15 Results

    Regeneron Pharmaceuticals (REGN) earned $1.1 billion in 4Q15, which translates to a 37% YoY (year-over-year) sales growth.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Factors That Will Determine Repatha’s Future Commercial Success

    Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.

    By Margaret Patrick
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///Eylea
    Earnings Report

    What Drove Regeneron’s 3Q16 Performance?

    In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

    By Jillian Dabney
  • uploads///Graph Autosomal recessive pattern
    Company & Industry Overviews

    BioMarin Leads in the Market for Mucopolysaccharidoses Disorders

    BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

    By Jillian Dabney
  • uploads///dupixent sales
    Company & Industry Overviews

    Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials

    Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug

    On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

    By Margaret Patrick
  • Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up
    Healthcare

    Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up

    Regeneron and Eli Lilly stocks are trending up after President Trump praise their COVID-19 treatment.
    By Ambrish Shah
  • Roche and Regeneron Partner on COVID-19 Drug
    Healthcare

    Regeneron to Partner With Roche on COVID-19 Drug

    Roche Holding has agreed to help develop and distribute an experimental COVID-19 drug in partnership with Regeneron Pharmaceuticals.
    By Ambrish Shah
  • uploads///ANR
    Company & Industry Overviews

    Why Are Most Analysts Recommending a ‘Buy’ for Vertex?

    On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.

    By Jillian Dabney
  • uploads///PE multiple
    Company & Industry Overviews

    Why Is Vertex Pharmaceuticals’ Valuation at a Discount?

    On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

    By Jillian Dabney
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte Was a Star Performer from August 10–17, 2015

    By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

    By Peter Neil
  • uploads///ANR
    Earnings Report

    What Can Investors Expect from Regeneron’s 4Q15 Earnings?

    Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.

    By Jillian Dabney
  • Healthcare

    Amgen has attractive, high-growth assets

    The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.

    By Samantha Nielson
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///AdobeStock_
    Earnings Report

    Regeneron Is Down despite Earnings Beat

    Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.

    By Margaret Patrick
  • uploads///scientist _
    Company & Industry Overviews

    Analysts Raise Their Target Price for Regeneron in March

    Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

    By Margaret Patrick
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Jazz Pharmaceuticals: Analysts’ View in November

    On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Revenue Growth Is Expected in Q3

    Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Stock Performance in September

    On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

    By Mike Benson
  • uploads///product approval timeline
    Company & Industry Overviews

    Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent

    On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///ALNY
    Earnings Report

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///microscope _
    Earnings Report

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Sarepta’s Second-Quarter Earnings

    Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Incyte’s Valuations on July 6

    Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

    On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

    By Margaret Patrick
  • uploads///ice cream cone _
    Materials

    The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It

    Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.

    By JP Gravitt
  • uploads///MEI
    Company & Industry Overviews

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

    By Daniel Collins
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Why Regeneron Pharmaceuticals’ Stock Price Fell

    Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Ophthalmology
    Company & Industry Overviews

    How Novartis’s Ophthalmology Business Performed in 2017

    In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///REGN Arcalyst sales
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Kevzara, Arcalyst, and Zaltrap

    In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ January 2018 Valuation

    On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Expects Eucrisa to Report Sales of ~$2.0 Billion

    Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]

    By Margaret Patrick
  • uploads///Ophthalmology
    Company & Industry Overviews

    Inside Novartis’s Ophthalmology Drugs Now

    In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Inclisiran: Long-Term Growth Driver for The Medicines Company?

    According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis

    Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

    By Margaret Patrick
  • uploads///Lucentis
    Company & Industry Overviews

    How Is Novartis’s Lucentis Positioned after 1H17?

    In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017

    Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Regulatory Approval in Asthma Indication May Boost Dupixent’s Sales

    In June 2017 and July 2017, healthcare providers wrote prescriptions for Regeneron (REGN) and Sanofi’s (SNY) Dupixent for 750 new patients on a weekly basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Eylea Leads the Retinal Diseases Sector

    In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron in September 2017

    Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

    By Margaret Patrick
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent and Kevzara: Regeneron’s Long-Term Growth Drivers?

    In 2Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $28.6 million.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals’ Valuation?

    Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

    By Mike Benson
  • uploads///Analysts Recommendations
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron in July 2017

    In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent Could Substantially Drive Regeneron’s Growth

    In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

    By Daniel Collins
  • uploads///Chart  BIIB
    Miscellaneous

    What Drove Biogen Stock in 2Q17?

    Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart  AMGN
    Miscellaneous

    The Rise of Amgen Stock in 2Q17

    Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Eosinophilic Esophagitis: Major Market Opportunity for Dupixent?

    Regeneron (REGN) has obtained positive results from its Phase 2 proof-of-concept study evaluating Dupixent in eosinophilic esophagitis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Prove Effective in Multiple Diseases

    Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion May Boost Regeneron’s Dupixent in the Future

    Regeneron (REGN) and Sanofi (SNY) are exploring the use of Dupixent in other indications such as asthma, pediatric AD, nasal polyps, and eosinophilic esophagitis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be a Major Growth Driver for Regeneron in 2017

    After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Regeneron Continues to Explore Eylea in Multiple New Indications

    To further expand Eylea’s label, Regeneron is studying the drug in combination with angiopoietin2 (or Ang2) antibody nesvacumab in two Phase 2 trials.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Repatha Clinical Trial Result
    Company & Industry Overviews

    Amgen’s Repatha Could Gain Market Share in 2017

    In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.

    By Daniel Collins
  • uploads///Amgen Revenue
    Company & Industry Overviews

    What Could Drive Amgen’s Growth in 2017?

    Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Dupixent Expected to Be a Solid Addition to Regeneron’s Portfolio

    On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Net Profit Margins Expected to Narrow in 2017

    Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Is Amgen’s Cardiovascular Segment Still a Growth Opportunity?

    As cardiovascular diseases cost the global society around $600 billion annually, this segment is a huge growth opportunity for the pharmaceutical industry.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why United Therapeutics Expects Strong Revenue Growth

    United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant Pharmaceuticals Could See Modest Revenue Decline in 2016

    In 3Q16, Valeant Pharmaceuticals (VRX) revised its fiscal 2016 revenue guidance downward from $9.9 billion–$10.1 billion to ~$9.6 billion to ~$9.7 billion. In 2016, VRX suffered from talent retention issues, negative press coverage, and litigation.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent Is Being Explored for Multiple Indications in 2016

    In addition to being explored as a monotherapy for AD (atopic dermatitis), Regeneron and Sanofi are also researching Dupixent for other indications.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent’s Label

    In Phase 3 trials, SOLO 1 and SOLO 2, Regeneron (REGN) and Sanofi (SNY) tested the efficacy of an investigational therapy, Dupixent, compared to a placebo.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent: Leading Therapy for Atopic Dermatitis in the Future?

    Existing treatment options for AD aren’t tolerated well by the entire patient population. Dupixent might become a preferred regimen in the future.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent Might Help Diversify Regeneron’s Business Model

    If Dupixent manages to secure FDA approval, it might have a positive impact on Regeneron’s share prices as well as those of the PowerShares QQQ (QQQ).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Neurocrine Biosciences May See Higher Losses in 2016

    Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

    By Margaret Patrick
  • uploads///orkambis success
    Earnings Report

    Why Europe Is an Important Market for Vertex’s Orkambi

    Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.

    By Jillian Dabney
  • uploads///Orkambi
    Company & Industry Overviews

    Higher Discontinuations Are among Orkambi’s Concerns

    Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

    By Jillian Dabney
  • uploads///sarilumab
    Company & Industry Overviews

    2016’s Estimated Product Launches: LixiLan, Sarilumab, Lixisenatide

    LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Regeneron’s Growth Opportunities: Praluent, Sarilumab, and Dupilumab

    Regeneron (REGN) and Sanofi (SNY) have submitted a supplemental BLA to the FDA for review for approving the 300mg monthly dosing of Praluent.

    By Margaret Patrick
  • uploads///soliris opportunity
    Earnings Report

    How Significant Is Alexion’s Opportunity with Soliris?

    Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

    By Jillian Dabney
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.